Cyclophilin Inhibitor NV556 Reduces Fibrosis and Hepatocellular Carcinoma Development in Mice With Non-Alcoholic Steatohepatitis

Hepatocellular carcinoma (HCC), the third major cause of cancer mortality, can result from non-alcoholic steatohepatitis (NASH). Due to limited efficacy of drugs approved for HCC and no drug available yet for NASH, identification of new effective treatments is crucial. Here, we investigated whether...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Front Pharmacol
Autores principales: Kuo, Joseph, Serrano, Sonia Simón, Grönberg, Alvar, Massoumi, Ramin, Hansson, Magnus Joakim, Gallay, Philippe
Formato: Artigo
Lenguaje:Inglês
Publicado: Frontiers Media S.A. 2019
Materias:
Pharmacology
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6775500/
https://ncbi.nlm.nih.gov/pubmed/31611801
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2019.01129
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares